Post Traumatic Stress Disorder Market: Rapid Growth & Investment Outlook to 2034 - DelveInsight | Pfizer, GlaxoSmithKline, KGK Science Inc., AstraZeneca, UCB Pharma, Bionorica SE, Bionomics Limited

The Key Post Traumatic Stress Disorder Companies in the market include - Nobilis Therapeutics, Otsuka Pharma, Compass Pathways, Aptinyx, Jazz Pharmaceuticals, COMPASS Pathways, Bionomics Limited, Boehringer Ingelheim, GlaxoSmithKline, KGK Science Inc., AstraZeneca, UCB Pharma, Bionorica SE, Bionomics Limited, Pfizer, and others.

DelveInsight's "Post Traumatic Stress Disorder Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Post Traumatic Stress Disorder, historical and forecasted epidemiology as well as the Post Traumatic Stress Disorder market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

To Know in detail about the Post Traumatic Stress Disorder market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Post Traumatic Stress Disorder Market Forecast [https://www.delveinsight.com/sample-request/post-traumatic-stress-disorder-ptsd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Post Traumatic Stress Disorder Market Report:

*
The Post Traumatic Stress Disorder market size was valued ~USD 1,760 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034).

*
In March 2026, PharmAla Biotech Holdings Inc. announced that it has entered into a Supply & Data Agreement with Nautilus Sanctuary Inc. to provide MDMA for use in a Phase 2 clinical trial in the United States. The company focuses on the research, development, and manufacturing of LaNeo Trademark MDMA and novel MDMA-based compounds (MDXX class molecules).

*
In December 2025, Freespira, Inc., developer of the first FDA-cleared digital therapeutic for panic attacks, panic disorder, and PTSD, announced a partnership with Brighton Marine, a non-profit organization supporting healthcare, housing, and well-being for service members and their families. Through this collaboration, Freespira's innovative treatment will now be accessible to Brighton Marine Health Plan members. This integration underscores Brighton Marine's dedication to leveraging cutting-edge solutions to enhance veterans' physical and mental health while ensuring equitable access to high-quality healthcare services.

*
In November 2025, Silo Pharma announced that it has selected Allucent, a global full-service clinical research organization, to assist with the planned Investigational New Drug (IND) application submission to the US FDA for a Phase 1 clinical trial of SPC-15 targeting posttraumatic stress disorder (PTSD).

*
In September 2025, The US Food and Drug Administration (FDA) has released a Complete Response Letter (CRL) addressed to Lykos Pharmaceuticals, revealing for the first time its decision to reject approval of MDMA-assisted therapy for posttraumatic stress disorder (PTSD). While Lykos received the decision in August 2024, the CRL was only made public this week. This disclosure aligns with the FDA's new initiative to publish 89 previously undisclosed CRLs and to make all future CRLs publicly available immediately after issuance.

*
In February 2025, The U.S. Military's Defense Health Agency (DHA) collaborated with the Global Coalition for Adaptive Research (GCAR) on a platform trial aimed at identifying treatments for post-traumatic stress disorder (PTSD) in active-duty service members and veterans. The Military and Veterans PTSD Adaptive Platform Clinical Trial (M-PACT) (NCT05422612) is a Phase II randomized, double-blind, placebo-controlled study designed to assess multiple potential pharmacotherapeutic interventions for PTSD over a 12-week treatment period.

*
In December 2024, Bionomics Limited (Nasdaq: BNOX), a clinical-stage biotechnology company specializing in first-in-class allosteric ion channel modulators for central nervous system (CNS) disorders with high unmet needs, announced that positive results from its Phase 2 ATTUNE study have been published in NEJM Evidence. Additionally, the findings were presented at the 63 Annual Meeting of the American College of Neuropsychopharmacology (ACNP) during the inaugural "Promising Targets" session.

*
In December 2024, Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Lundbeck LLC announced that the complete results of a Phase 3 trial evaluating brexpiprazole in combination with sertraline for adult PTSD treatment have been published in JAMA Psychiatry. The findings demonstrated that patients receiving brexpiprazole with sertraline experienced a statistically significant greater improvement in PTSD symptoms compared to those treated with sertraline plus placebo, as measured by the change in Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) total score from Week 1 to Week 10.

*
In May 2024, Otsuka Pharmaceutical Development & Commercialization and Lundbeck Pharmaceuticals announced findings from three clinical trials investigating the effectiveness of brexpiprazole combined with sertraline for treating adults with post-traumatic stress disorder (PTSD). The trials included a Phase II study (Trial 061) and two Phase III studies (Trial 071 and 072), evaluating the safety and efficacy of this combination therapy.

*
In 2023, there were approximately 13.8 million prevalent cases of PTSD across the 7MM. These numbers are projected to rise in the forecasted period. The highest prevalence of PTSD cases was noted in the United States.

*
In the EU4 countries and the UK, there were approximately 3.387 million prevalent cases of PTSD in 2023, with expectations for an increase in the forecasted period.

*
In 2023, there were around 4.201 million cases of PTSD among males and approximately 9.6 million cases among females across the 7MM.

*
In 2023, PTSD cases were categorized by severity as approximately 4.43 million cases for mild, around 4.36 million cases for moderate, and about 5 million cases for severe across the 7MM.

*
In 2023, the total number of treated PTSD cases was approximately 2.5 million across the 7MM, with expectations for an increase during the forecast period.

*
Key Post Traumatic Stress Disorder Companies: Nobilis Therapeutics, Otsuka Pharma, Compass Pathways, Aptinyx, Jazz Pharmaceuticals, COMPASS Pathways, Bionomics Limited, Boehringer Ingelheim, GlaxoSmithKline, KGK Science Inc., AstraZeneca, UCB Pharma, Bionorica SE, Bionomics Limited, Pfizer, and others

*
Key Post Traumatic Stress Disorder Therapies: REXULTI plus-minus ZOLOFT, NBTX001, Brexpiprazole, COMP360, NYX-783, JZP150, Psilocybin, BNC210, BI 1358894, orvepitant, Psilocybin, Quetiapine Fumarate, levetiracetam, BX-1, BNC210, Ziprasidone, and others

*
The Post Traumatic Stress Disorder epidemiology based on gender analyzed that females are more affected with PTSD than females

*
The Post Traumatic Stress Disorder market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Post Traumatic Stress Disorder pipeline products will significantly revolutionize the Post Traumatic Stress Disorder market dynamics.

Post Traumatic Stress Disorder Overview

A person who has experienced or witnessed a traumatic event, such as a natural disaster, a serious accident, a terrorist act, war or combat, or who has been threatened with death assault, or serious injury, may develop post-traumatic stress disorder (PTSD), a chronic psychiatric disorder.

Get a Free sample for the Post Traumatic Stress Disorder Market Report -

https://www.delveinsight.com/report-store/post-traumatic-stress-disorder-ptsd-market [https://www.delveinsight.com/report-store/post-traumatic-stress-disorder-ptsd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Post Traumatic Stress Disorder Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Post Traumatic Stress Disorder Epidemiology Segmentation:

The Post Traumatic Stress Disorder market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

*
Total Prevalence of Post Traumatic Stress Disorder

*
Prevalent Cases of Post Traumatic Stress Disorder by severity

*
Gender-specific Prevalence of Post Traumatic Stress Disorder

*
Diagnosed Cases of Episodic and Chronic Post Traumatic Stress Disorder

Download the report to understand which factors are driving Post Traumatic Stress Disorder epidemiology trends @ Post Traumatic Stress Disorder Epidemiology Forecast [https://www.delveinsight.com/sample-request/post-traumatic-stress-disorder-ptsd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Post Traumatic Stress Disorder Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Post Traumatic Stress Disorder market or expected to get launched during the study period. The analysis covers Post Traumatic Stress Disorder market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Post Traumatic Stress Disorder Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Post Traumatic Stress Disorder Therapies and Key Companies

*
REXULTI plus-minus ZOLOFT: Otsuka Pharmaceutical

*
NBTX001: Nobilis Therapeutics

*
Brexpiprazole: Otsuka Pharma

*
COMP360: Compass Pathways

*
NYX-783: Aptinyx

*
JZP150: Jazz Pharmaceuticals

*
Psilocybin: COMPASS Pathways

*
BNC210: Bionomics Limited

*
BI 1358894: Boehringer Ingelheim

*
orvepitant: GlaxoSmithKline

*
Psilocybin: KGK Science Inc.

*
Quetiapine Fumarate: AstraZeneca

*
levetiracetam: UCB Pharma

*
BX-1: Bionorica SE

*
Ziprasidone: Pfizer

Discover more about therapies set to grab major Post Traumatic Stress Disorder market share @ Post Traumatic Stress Disorder Medications [https://www.delveinsight.com/sample-request/post-traumatic-stress-disorder-ptsd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Post Traumatic Stress Disorder Market Strengths

*
New diagnostic categories modeled on PTSD have been proposed, including prolonged duress stress disorder, post-traumatic grief disorder, post-traumatic relationship syndrome, post-traumatic dental care anxiety, and post-traumatic abortion syndrome.

Post Traumatic Stress Disorder Market Opportunities

*
The introduction of novel drugs and the class of new therapeutic drugs to treat PTSD in the market will bring hope to the PTSD patients as a therapeutic option and might have a major positive effect on the market.

Scope of the Post Traumatic Stress Disorder Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Post Traumatic Stress Disorder Companies: Nobilis Therapeutics, Otsuka Pharma, Compass Pathways, Aptinyx, Jazz Pharmaceuticals, COMPASS Pathways, Bionomics Limited, Boehringer Ingelheim, GlaxoSmithKline, KGK Science Inc., AstraZeneca, UCB Pharma, Bionorica SE, Bionomics Limited, Pfizer, and others

*
Key Post Traumatic Stress Disorder Therapies: REXULTI plus-minus ZOLOFT, NBTX001, Brexpiprazole, COMP360, NYX-783, JZP150, Psilocybin, BNC210, BI 1358894, orvepitant, Psilocybin, Quetiapine Fumarate, levetiracetam, BX-1, BNC210, Ziprasidone, and others

*
Post Traumatic Stress Disorder Therapeutic Assessment: Post Traumatic Stress Disorder current marketed and Post Traumatic Stress Disorder emerging therapies

*
Post Traumatic Stress Disorder Market Dynamics: Post Traumatic Stress Disorder market drivers and Post Traumatic Stress Disorder market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Post Traumatic Stress Disorder Unmet Needs, KOL's views, Analyst's views, Post Traumatic Stress Disorder Market Access and Reimbursement

To know more about Post Traumatic Stress Disorder companies working in the treatment market, visit @ Post Traumatic Stress Disorder Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/post-traumatic-stress-disorder-ptsd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Post Traumatic Stress Disorder Market Report Introduction

2. Executive Summary for Post Traumatic Stress Disorder

3. SWOT analysis of Post Traumatic Stress Disorder

4. Post Traumatic Stress Disorder Patient Share (%) Overview at a Glance

5. Post Traumatic Stress Disorder Market Overview at a Glance

6. Post Traumatic Stress Disorder Disease Background and Overview

7. Post Traumatic Stress Disorder Epidemiology and Patient Population

8. Country-Specific Patient Population of Post Traumatic Stress Disorder

9. Post Traumatic Stress Disorder Current Treatment and Medical Practices

10. Post Traumatic Stress Disorder Unmet Needs

11. Post Traumatic Stress Disorder Emerging Therapies

12. Post Traumatic Stress Disorder Market Outlook

13. Country-Wise Post Traumatic Stress Disorder Market Analysis (2020-2034)

14. Post Traumatic Stress Disorder Market Access and Reimbursement of Therapies

15. Post Traumatic Stress Disorder Market Drivers

16. Post Traumatic Stress Disorder Market Barriers

17. Post Traumatic Stress Disorder Appendix

18. Post Traumatic Stress Disorder Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=post-traumatic-stress-disorder-market-rapid-growth-investment-outlook-to-2034-delveinsight-pfizer-glaxosmithkline-kgk-science-inc-astrazeneca-ucb-pharma-bionorica-se-bionomics-limited]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.